TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32899071
Drug: Chemotherapy containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy containing bevacizumab (modified folinic acid, bolus/continuous fluorouracil, and oxaliplatin)
Study: 33664161
Drug: Sham training,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham training, no training, standard treatment, or breathing exercises
Study: 33487789
Drug: Single-session therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-session therapy
Study: 33487789
Drug: Multi-session therapy
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-session therapy
Study: 33052760
Drug: Camrelizumab 200
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Camrelizumab 200 mg every 2 weeks and apatinib 250 mg once per day
Study: 33228511
Drug: Omacor 1
Normalized name: Omacor 1 GM Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omacor 1 g/day
Study: 32947389
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no MMC treatment)
Study: 33417663
Drug: 1.3 g/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.3 g/kg/day protein plus placebo
Study: 33417663
Drug: 0.8 g/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g/kg/day protein plus placebo
Study: 33417663
Drug: 0.8 g/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g/kg/day protein plus testosterone enanthate 100 mg weekly
Study: 33417663
Drug: 1.3 g/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.3 g/kg/day protein plus testosterone enanthate 100 mg weekly
Study: 32379280
Drug: Durvalumab (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (1500 mg every 28 days) plus Tremelimumab (75 mg every 28 days for the first 4 cycles)
Study: 34278827
Drug: Neoadjuvant osimertinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant osimertinib with or without chemotherapy
Study: 33090219
Drug: Radiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy with or without androgen deprivation therapy
Study: 35932065
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB)
Study: 35636205
Drug: Zero-opioid (ZO)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zero-opioid (ZO) protocol (same as OS but no opioid prescriptions at discharge)
Study: 34341423
Drug: High DHM
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High DHM group (D group) with 359.12 mg/g DHM
Study: 34341423
Drug: Low DHM
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low DHM group (B group) with 210.31 mg/g DHM
Study: 35312948
Drug: Transversus abdominis
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transversus abdominis plane block (TAPB) with 30 ml 0.33% ropivacaine and dexmedetomidine 1 μg kg−1
Study: 35312948
Drug: Quadratus lumborum
Normalized name: Pisum quadratum whole
DrugBank: Pisum sativum whole (DB15545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadratus lumborum block (QLB) with 30 ml 0.33% ropivacaine and dexmedetomidine 1 μg kg−1
Study: 35312948
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia (GA) with 30 ml 0.9% saline
Study: 33912695
Drug: Standard systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard systemic therapy with local ablative radiotherapy
Study: 33206263
Drug: Early antiretroviral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early antiretroviral treatment (ART) initiation irrespective of CD4 count
Study: 33159573
Drug: Localized heat
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Localized heat therapy (heat pads applied for 8 hours/day, 5 days/week on one randomly selected calf)
Study: 33081444
Drug: Tenoten for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoten for children (1 tablet 3 times a day)
Study: 33081444
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 tablet 3 times a day)
Study: 33710154
Drug: 0.1 M STS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 M STS gel
Study: 32007430
Drug: Low-intensity extracorporeal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity extracorporeal shockwave therapy (LiESWT) combined with tadalafil (5 mg/day)
Study: 32007430
Drug: Tadalafil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (5 mg/day) alone
Study: 35196426
Drug: Antiseizure medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiseizure medications plus standard care
Study: 35278695
Drug: Rhythm control
Normalized name: ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY 180 mg in 1 g TOPICAL STICK [ZUSKA RHYTHM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhythm control (pharmaceutical or electrical cardioversion)
Study: 35278695
Drug: Rate control
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rate control (b-blocker, digoxin, calcium channel blockers)
Study: 32179526
Drug: Dihydroartemisinin‐piperaquine (DP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin‐piperaquine (DP) + single low dose of primaquine (SLDPQ; 0.25 mg/kg)
Study: 32746734
Drug: Immersive VR
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immersive VR experience after control treatment
Study: 32746734
Drug: Overall satisfaction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall satisfaction with VR treatment
Study: 33196866
Drug: Palliative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Palliative radiation therapy (RT)
Study: 35296994
Drug: Sintilimab plus
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab plus Bevacizumab (7.5 mg/kg dose of Bevacizumab)
Study: 35684003
Drug: Fermented Carica
Normalized name: Carica papaya preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented Carica papaya and Morinda citrifolia (28g twice per day for 20 days)
Study: 32091548
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D supplementation (2800 IU/d)
Study: 32091548
Drug: Standard-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose vitamin D supplementation (400 IU/d)
Study: 32446880
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment focusing on lifestyle recommendations (ST)
Study: 34647961
Drug: Active supplement
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active supplement (125 mg L‐lysine, 40 mg vitamin C, 26.3 mg Vitis vinifera extract, 5 mg zinc, 100 mg Citrus aurantium)
Study: 34647961
Drug: Active supplement
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active supplement
Study: 33009241
Drug: Amlodipine/valsartan 5/80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/valsartan 5/80 mg FDC
Study: 33109240
Drug: Adalimumab (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (20 mg biweekly if < 30 kg or 40 mg biweekly if ≥ 30 kg)
Study: 34214210
Drug: Perhexiline (150-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perhexiline (150-600 ng/mL)
Study: 35404074
Drug: GST‐HG131 10-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: GST‐HG131 10-300 mg (single ascending dose)
Study: 35404074
Drug: GST‐HG131 30-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: GST‐HG131 30-60 mg BID (multiple ascending dose)
Study: 35404074
Drug: GST‐HG131 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GST‐HG131 100 mg (multiple ascending dose)
Study: 35404074
Drug: GST‐HG131 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GST‐HG131 100 mg (food effect)
Study: 35490165
Drug: JDE exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: JDE exercise program for 12 weeks, twice a week for 45 minutes each
Study: 35203087
Drug: Clonidine 4
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine 4 µg/kg
Study: 32614361
Drug: AqualiefTM (carnosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: AqualiefTM (carnosine and dried calyces of Hibiscus sabdariffa L.)
Study: 33131126
Drug: Adjuvant allergen
Normalized name: catfish allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant allergen immunotherapy (AIT)
Study: 35763249
Drug: SBRT +
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBRT + Abiraterone acetate 1000 mg and oral prednisone 10 mg daily
Study: 35763249
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (GnRH agonist or antagonist plus abiraterone acetate 1000 mg and oral prednisone 10 mg daily)
Study: 32693855
Drug: Monthly nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly nutrition education and counselling (NEC) during pregnancy and infancy period
Study: 34057183
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 μg/kg bolus at induction, followed by 0.6 μg/kg/h infusion until emergence), n = 75
Study: 34057183
Drug: Placebo infusion,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion, n = 75
Study: 34753183
Drug: Physical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Therapy (PT), Occupational Therapy (OT), Speech Therapy (ST)
Study: 32779001
Drug: β1 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: β1 + 2 AR antagonist (nadolol)
Study: 32779001
Drug: β1 AR
Normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: β1 AR antagonist (bisoprolol)
Study: 32883371
Drug: Ibuprofen in
Normalized name: ibuprofen Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen in combination with acetaminophen
Study: 32883371
Drug: Ibuprofen in
Normalized name: ibuprofen Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen in combination with hydromorphone
Study: 32883371
Drug: Ibuprofen alone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen alone, Ibuprofen + Acetaminophen, Ibuprofen + Hydromorphone
Study: 38241247
Drug: Inhaled nitrous
Normalized name: nitrous oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitrous oxide
Study: 32186924
Drug: Mothers and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mothers and Babies Course (a six-week Spanish cognitive behavioural therapy group intervention)
Study: 36278293
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (Zhejiang Xianju Pharmaceutical Co., Ltd., China)
Study: 36278293
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (Medrol, Pfizer Italia SRL)
Study: 33113088
Drug: Concurrent trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent trastuzumab and chemotherapy
Study: 33113088
Drug: Sequential trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential trastuzumab after chemotherapy
Study: 35564330
Drug: Satir Transformational
Normalized name: Vagisil Satin
DrugBank: Hydrocortisone acetate (DB14539)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Satir Transformational Systemic Therapy (STST) group counseling intervention
Study: 35564330
Drug: Control/no treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control/no treatment
Study: 32456236
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (no treatment) as control group.
Study: 35109960
Drug: Montmorency cherries
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montmorency cherries (30 ml twice daily)
Study: 35672660
Drug: DexP group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: DexP group (60 µg of dexmedetomidine added to ropivacaine)
Study: 34569482
Drug: Molidustat (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molidustat (25 mg or 50 mg once daily)
Study: 32067633
Drug: Azithromycin (∼20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (∼20 mg/kg)
Study: 37952176
Drug: Dapagliflozin, 10
Normalized name: Dapagliflozin, 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin, 10 mg per day
Study: 32951241
Drug: Pre-mixed nitrous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-mixed nitrous oxide/oxygen mixture treatment
Study: 32951241
Drug: Medical air
Normalized name: Medical air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical air treatment
Study: 34116176
Drug: Ciprofol 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofol 0.4 mg/kg
Study: 34116176
Drug: Propofol 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2.0 mg/kg
Study: 33580595
Drug: Resveratrol supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol supplementation (1,000 mg for 8 weeks)
Study: 33340674
Drug: NO3−‐rich beetroot
Approvals — FDA: no, EMA: no, PMDA: no
Description: NO3−‐rich beetroot powder (5 g/d contains 250 mg NO3−)
Study: 34810362
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard tapered root form implant without pretreatment)
Study: 32353342
Drug: Abemaciclib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib (150 mg orally every 12 hours on days 1-21 of a 21-day cycle), trastuzumab (8 mg/kg on cycle 1 day 1, then 6 mg/kg on day 1 of each subsequent cycle), and fulvestrant (500 mg on days 1, 15, and 29, then once every 4 weeks thereafter)
Study: 32353342
Drug: Abemaciclib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib (150 mg orally every 12 hours on days 1-21 of a 21-day cycle) and trastuzumab (8 mg/kg on cycle 1 day 1, then 6 mg/kg on day 1 of each subsequent cycle)
Study: 32353342
Drug: Standard-of-care chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care chemotherapy plus trastuzumab
Study: 35729605
Drug: Voice-activated delivery
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voice-activated delivery of cognitive behavioral therapy for insomnia (CBT-I) components using a smart speaker device for 6 weeks.
Study: 35392766
Drug: Inhaling 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaling 800 µg salbutamol
Study: 32493276
Drug: Lidocaine 2%
Normalized name: LIDOCAINE 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2% (intravenous bolus 1.5 mg/kg followed by an infusion of 2 mg/kg/h)
Study: 36098028
Drug: Integrated multidomain
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated multidomain intervention (16 2-hour sessions per year including physical exercise, cognitive training, nutrition and disease education, plus individualized treatment by specialists)
Study: 33378495
Drug: 400 g
Normalized name: Ambi 60 PSE-400 GFN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 g of intrusive force
Study: 33378495
Drug: 200 g
Normalized name: PEG-200 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 g of intrusive force
Study: 35841908
Drug: Rituximab (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (1000 mg followed by 500 mg every 6 months)
Study: 35841908
Drug: Dimethyl fumarate
Normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dimethyl fumarate (240 mg twice daily)
Study: 36153457
Drug: Pricking and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pricking and cupping therapy + Chinese herbal wet compress + basic treatment
Study: 36153457
Drug: Pricking and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pricking and cupping + basic treatment
Study: 36153457
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal wet compress + basic treatment
Study: 33527413
Drug: UltraAC (Ultraconservative
Approvals — FDA: no, EMA: no, PMDA: no
Description: UltraAC (Ultraconservative access cavity preparation)
Study: 33527413
Drug: TradAC (Traditional
Approvals — FDA: no, EMA: no, PMDA: no
Description: TradAC (Traditional access cavity preparation)
Study: 33626877
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose of protamine (1 mg per mg heparin used)
Study: 33626877
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose of protamine (0.8 mg per mg heparin used)
Study: 32537643
Drug: Modestly lower
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modestly lower carbohydrate diet (MLC, ∼135 g/d carbohydrate)
Study: 32537643
Drug: Routine care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine care (RC, ∼200 g/d carbohydrate)
Study: 32897368
Drug: Suptavumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suptavumab (1 dose)
Study: 32897368
Drug: Suptavumab (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suptavumab (2 doses)
Study: 32856379
Drug: Daily life
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily life activities simulation
Study: 33481114
Drug: Joy Luck
Approvals — FDA: no, EMA: no, PMDA: no
Description: Joy Luck Academy program (weekly education and peer-mentor support sessions)
Study: 35909334
Drug: Iron–folic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron–folic acid (IFA) capsule (control)
Study: 35909334
Drug: Multiple micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple micronutrient (MMN) capsule of 18 micronutrients (second control)
Study: 34158672
Drug: Mucolytic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucolytic solution (100 mL water + 400 mg N-acetylcysteine + 20 mg simethicone)
Study: 34158672
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (without the solution)
Study: 34158672
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (100 mL pure water)
Study: 34491648
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus medication (horizontal penetration needling combined with rizatriptan monobenzoate tablets)
Study: 34491648
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication (rizatriptan monobenzoate tablets 10 mg)
Study: 32293363
Drug: Chronobiological Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronobiological Therapy (CT)
Study: 32293363
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT‐I) + Chronobiological Therapy (CT)
Study: 35722977
Drug: Perilla frutescens
Normalized name: perilla frutescens top
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perilla frutescens seed oil (PO) 1.47 mL daily (0.88 g ALA)
Study: 35722977
Drug: Perilla frutescens
Normalized name: perilla frutescens top
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perilla frutescens seed oil (PO) 1.47 mL daily (0.88 g ALA) and Anredera cordifolia leaf powder 1.12 g daily (1.46 mg vitexin and 1.12 mg adenosine)
Study: 32653012
Drug: Protein-only group
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-only group receiving dairy products to increase protein intake to 1.5 g/kg/day
Study: 33934456
Drug: Dasiglucagon (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasiglucagon (0.6 mg)
Study: 35222900
Drug: Acupoint injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint injection of mecobalamin
Study: 35152575
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of acupoint injection and Vitalstim electrical stimulation
Study: 34392865
Drug: Slide presentation
Normalized name: Chamois Glide
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Slide presentation (Group 1; SP‐G)
Study: 34392865
Drug: Video clip
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Video clip (Group 2; V‐G)
Study: 35856588
Drug: Chlorhexidine (di)gluconate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine (di)gluconate lock solution (CHGLS)
Study: 34040400
Drug: Naproxen (375-500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (375-500 mg twice daily)
Study: 33731384
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor use
Study: 34909917
Drug: Oral pilocarpine
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral pilocarpine (20 mg daily)
Study: 33639559
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of feedback and modeling
Study: 33906609
Drug: Initial heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial heparin dose of 100 U/kg (Warfarin group)
Study: 33906609
Drug: Initial heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial heparin dose of 110 U/kg (NOAC group)
Study: 33906609
Drug: Initial heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial heparin dose of 120 U/kg (NOAC group)
Study: 33906609
Drug: Initial heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial heparin dose of 130 U/kg (NOAC group)
Study: 32602755
Drug: Topical oxymetazoline
Normalized name: oxymetazoline Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical oxymetazoline (OXZ) 1.5% in liposomal base
Study: 32602755
Drug: Topical lipogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lipogel (control)
Study: 33595845
Drug: Benralizumab 30
Normalized name: benralizumab 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benralizumab 30 mg SC
Study: 33157937
Drug: 8-week mindfulness-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-week mindfulness-based cognitive therapy program